BCR-ABL-IN-6
BCR-ABL-IN-6 (9h) is a selective Bcr-Abl kinase inhibitor with IC50s of 4.6 and 227 nM for Bcr-AblWT and Bcr-AblT3151 respectively. BCR-ABL-IN-6 inhibits Bcr-Abl kinase with strong affinity inside the cells with an EC50 of 14.6 nM. BCR-ABL-IN-6 is an imatinib derivative which can be used for research of chronic myelogenous leukemia. BCR-ABL-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2499499-26-0
- 分子式: C27H22F3N5O2
- 分子量:505.49
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
IC50: 4.6 nM (Bcr-AblWT), 227 nM (Bcr-AblT3151)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | GI50 |
1.36 μM
Compound: 9h
|
Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 32961435] |
| HL-60(TB) | GI50 |
1.4 μM
Compound: 9h
|
Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 32961435] |
| K562 | GI50 |
<0.01 μM
Compound: 9h
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 32961435] |
| K562 | GI50 |
0.02 μM
Compound: 9h
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32961435] |
| L132 | GI50 |
9.27 μM
Compound: 9h
|
Antiproliferative activity against human L132 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human L132 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32961435] |
| MOLT-4 | GI50 |
1.31 μM
Compound: 9h
|
Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 32961435] |
| RPMI-8226 | GI50 |
1.98 μM
Compound: 9h
|
Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 32961435] |
| SR | GI50 |
2.4 μM
Compound: 9h
|
Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 32961435] |
体外実験
BCR-ABL-IN-6 (10 μM; 1 h) againts with c-Src which is a closely related kinase domain of Bcr-Abl and exerts superior cellular potencies to imatinib[1]. BCR-ABL-IN-6 (10 μM; 1 h) suppresses Bcr-Abl phosphorylation dose dependenly and results underscored selective antiproliferative effects towards Bcr-Abl [1]. BCR-ABL-IN-6 (10 μM; 1 h) shows great selectivity cytotoxic between K562 and L132 cells[1]. BCR-ABL-IN-6 (10 μM) shows strong cytostatic activity against K562 and HL60 cells[1]. BCR-ABL-IN-6 (10 μM) shows exceptional selective antiproliferative effects towards the Bcr-Abl positive leukemia cell K562[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:K562 cell line
-
Concentration:0.003, 0.01, 0.03, 0.1 and 0.3 μM
-
Incubation Time:1 h
-
Result:Showed a dose-dependent suppression of Bcr-Abl phosphorylation.
-
Cell Line:K562 and L132 cell lines
-
Concentration:10 μM
-
Incubation Time:1 h
-
Result:Exerted cellular activity with GI50 less than 160 nM against the Bcr-Abl positive leukemia K562 cells and exerted superior cellular potencies to imatinib with GI50 of 0.02 μM. Showed selectivity cytotoxic effects to the normal cell L132 with GI50 of 9.27 μM.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male ICR mice[1]
-
Dosage:5 mg/kg and 10 mg/kg
-
Administration:Intravenous and oral; 5 and 10 mg/kg; for 9h
-
Result:Oral administration is not as effective as intravenous injection, intravenous injection is better.
化学情報
-
CAS 番号 2499499-26-0
-
分子量 505.49
-
分子式 C27H22F3N5O2
-
SMILES
O=C(NC1=CC=CC(C#CC2=CC=CC3=C2C(N)=NN3)=C1)C4=CC=C(N5CCOCC5)C(C(F)(F)F)=C4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. El-Damasy AK, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity[J]. European Journal of Medicinal Chemistry, 2020, 207:112710. [Content Brief]
[2]. El-Damasy AK, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity[J]. European Journal of Medicinal Chemistry, 2020, 207:112710. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)